TriSalus Life Sciences, Inc. (TLSI)
2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| Revenue | 11,213 | 9,167 | 7,349 | 7,364 |
| Cost of goods sold | 1,802 | 1,495 | 1,004 | 912 |
| Gross profit | 9,411 | 7,672 | 6,345 | 6,452 |
| General and administrative | 5,657 | 4,971 | 4,727 | 3,956 |
| Research and development | 3,923 | 3,296 | 4,219 | 4,666 |
| Sales and marketing | 7,163 | 6,734 | 6,138 | 6,004 |
| Loss from operations | -7,332 | -7,329 | -8,739 | -8,174 |
| Interest income | 134 | 74 | 158 | 97 |
| Interest expense | 1,423 | 1,209 | 1,142 | - |
| Change in fair value of contingent earnout liability | -700 | 820 | -2,360 | -13,689 |
| Change in fair value of sepa, warrant, and revenue base redemption liabilities | -330 | -835 | 4,974 | -9,016 |
| Other expense, net | -40 | -251 | -13 | -44 |
| Interest expense | - | - | - | 877 |
| Loss before income taxes | -8,291 | -10,370 | -2,402 | -4,325 |
| Income tax benefit (expense) | -3 | 5 | -3 | 7 |
| Net loss available to common stockholders | -8,288 | -10,375 | -2,399 | -4,332 |
| Undeclared dividends on series a preferred stock | 714 | 712 | 803 | 801 |
| Net loss attributable to common stockholders | -9,002 | -11,087 | -3,202 | -5,133 |
| Net loss per common share, basic (in dollars per share) | -0.27 | -0.39 | -0.12 | -0.21 |
| Net loss per common share, diluted (in dollars per share) | -0.27 | -0.39 | -0.12 | -0.21 |
| Weighted average common shares outstanding, basic (in shares) | 32,899,297 | 28,527,453 | 26,501,597 | 23,903,659 |
| Weighted average common shares outstanding, diluted (in shares) | 32,899,297 | 28,527,453 | 26,501,597 | 23,903,659 |